On May 13, MSD (MRK.US) announced the latest progress of PD-1 antibody+tiGIT antibody combined adjuvant treatment for operable high-risk melanoma phase III clinical KeyVibe-010. Compared with the combination treatment group, the study is unlikely to reach the main end of RFS due to the higher discontinuation rate compared to the PD-1 single-drug treatment group (mainly due to immune-related side effects). Following the IDMC recommendation, MSD terminated the phase III clinical trial and revealed blindness. Patients in the combination treatment group can choose to continue to receive PD-1 monotherapy.
默沙东(MRK.US)终止PD-1+TIGIT辅助治疗黑色素瘤三期临床
MSD (MRK.US) terminates PD-1 plus TIGIT adjuvant treatment of melanoma phase III
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.